Home / Market News / $LSTA
fiscal.ai Corporate Catalyst Impact 90/100 ● negative

Lisata Therapeutics Reports Third Quarter 2026 Financial Results

Nov 15, 2026, 2:09 PM UTC · Primary ticker $LSTA

Lisata Therapeutics reported a significant widening of its operating loss to $10.03 million in Q3 2026, up from $4.41 million in the prior year, with no revenue generated. This substantial increase in losses, coupled with negative EPS, indicates deteriorating financial performance and will likely be viewed negatively by investors.

Lisata Therapeutics announced its third-quarter 2026 financial results, revealing zero revenue for the period, consistent with the prior year. The most critical development is the substantial increase in operating loss, which more than doubled from $4.41 million in Q3 2025 to $10.03 million in Q3 2026. This widening loss, alongside a more negative diluted EPS of -$0.73, signals a significant deterioration in the company's financial health. For traders, this indicates increased cash burn and a longer path to profitability, likely leading to downward pressure on the stock in the short term. The long-term implications depend on the company's ability to generate revenue or secure additional funding, as continued losses at this rate are unsustainable.

$LSTA negative Widening operating loss and negative EPS
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.